PT1893196E - Composto de diaril-hidantoína - Google Patents

Composto de diaril-hidantoína

Info

Publication number
PT1893196E
PT1893196E PT06748863T PT06748863T PT1893196E PT 1893196 E PT1893196 E PT 1893196E PT 06748863 T PT06748863 T PT 06748863T PT 06748863 T PT06748863 T PT 06748863T PT 1893196 E PT1893196 E PT 1893196E
Authority
PT
Portugal
Prior art keywords
diaril
hydantoin compound
hydantoin
compound
synthesizing
Prior art date
Application number
PT06748863T
Other languages
English (en)
Portuguese (pt)
Inventor
Charles L Sawyers
Michael E Jung
Charlie D Chen
Samedy Ouk
Derek Welsbie
Chris Tran
John Wongvipat
Dongwon Yoo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1893196(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PT1893196E publication Critical patent/PT1893196E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PT06748863T 2005-05-13 2006-03-29 Composto de diaril-hidantoína PT1893196E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68083505P 2005-05-13 2005-05-13
US75035105P 2005-12-15 2005-12-15
US75655206P 2006-01-06 2006-01-06

Publications (1)

Publication Number Publication Date
PT1893196E true PT1893196E (pt) 2012-04-03

Family

ID=37431537

Family Applications (2)

Application Number Title Priority Date Filing Date
PT06748863T PT1893196E (pt) 2005-05-13 2006-03-29 Composto de diaril-hidantoína
PT111844015T PT2444085E (pt) 2005-05-13 2006-03-29 Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111844015T PT2444085E (pt) 2005-05-13 2006-03-29 Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro

Country Status (29)

Country Link
EP (5) EP3106162A1 (enExample)
JP (13) JP4644737B2 (enExample)
KR (12) KR101431407B1 (enExample)
CN (6) CN102584712A (enExample)
AT (1) ATE541571T1 (enExample)
AU (1) AU2006248109B2 (enExample)
BE (1) BE2013C074I2 (enExample)
BR (1) BRPI0610359B8 (enExample)
CA (1) CA2608436C (enExample)
CY (2) CY1112798T1 (enExample)
DK (2) DK2444085T3 (enExample)
ES (2) ES2535179T3 (enExample)
HK (1) HK1217103A1 (enExample)
HR (2) HRP20120323T4 (enExample)
HU (1) HUS1300076I1 (enExample)
IL (4) IL187328A (enExample)
LU (1) LU92338I2 (enExample)
ME (1) ME01992B (enExample)
MX (4) MX2007014132A (enExample)
NO (4) NO339997B1 (enExample)
NZ (3) NZ591119A (enExample)
PL (2) PL1893196T5 (enExample)
PT (2) PT1893196E (enExample)
RS (2) RS52274B2 (enExample)
RU (3) RU2448096C3 (enExample)
SG (1) SG10201703816SA (enExample)
SI (2) SI1893196T2 (enExample)
WO (1) WO2006124118A1 (enExample)
ZA (2) ZA200710870B (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP3106162A1 (en) * 2005-05-13 2016-12-21 The Regents of the University of California Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
WO2008093838A1 (ja) * 2007-02-01 2008-08-07 Chugai Seiyaku Kabushiki Kaisha スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
MX2011008858A (es) * 2009-02-24 2012-01-27 Medivation Prostate Therapeutics Inc Compuestos de diarilhidantoina y diariltiohidantoina especificos.
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
ES2707598T3 (es) * 2009-05-12 2019-04-04 Koninklijke Philips Nv Fosfodiesterasa 4D7 como marcador para cáncer maligno de próstata sensible a hormonas
JP5659232B2 (ja) * 2009-09-10 2015-01-28 トン、ヨウヂ アンドロゲン受容体アンタゴニストおよびその使用
US20120238533A1 (en) 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US8722695B2 (en) 2009-12-11 2014-05-13 Autifony Therapeutics Limited Imidazolidinedione derivatives
HUE037389T2 (hu) 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
ES2671343T3 (es) 2010-02-24 2018-06-06 Medivation Prostate Therapeutics Llc Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
DK2649066T3 (en) 2010-12-06 2016-01-11 Autifony Therapeutics Ltd Hydantoin derivatives using as KV3 inhibitors.
WO2012119559A1 (en) 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
US8921378B2 (en) 2011-04-21 2014-12-30 Orion Corporation Androgen receptor modulating carboxamides
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
DK2739153T3 (en) 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
CA2856646C (en) 2011-11-30 2020-01-14 Astrazeneca Ab Combination treatment of cancer
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
JP6262733B2 (ja) * 2012-09-04 2018-01-17 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
BR112015005404A2 (pt) * 2012-09-11 2017-08-22 Dr Reddys Laboratories Ltd Formas polimórficas de enzalutamida e sua preparação
EP4450130A3 (en) * 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
US9944607B2 (en) 2012-10-16 2018-04-17 Whitehead Institute For Biomedical Research Thiohydantoin derivatives and uses thereof
AU2013334102B2 (en) 2012-10-26 2018-08-16 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
CA3105575A1 (en) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP2016526538A (ja) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
CA2921156A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
WO2015063720A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
US20160318875A1 (en) 2013-12-16 2016-11-03 Sun Pharmaceutical Industries Limited Processes and intermediates for the preparation of enzalutamide
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
WO2015121768A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
EP3166931A4 (en) * 2014-07-11 2018-05-09 Shilpa Medicare Limited An improved process for the preparation of enzalutamide
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN104610111A (zh) * 2014-12-26 2015-05-13 杭州和泽医药科技有限公司 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法
CN105523958B (zh) * 2015-01-13 2017-11-03 北京海步医药科技股份有限公司 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX390189B (es) * 2015-01-20 2025-03-20 Arvinas Operations Inc COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs.
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
CN107635969B (zh) 2015-05-29 2021-08-17 安斯泰来制药有限公司 恩杂鲁胺结晶形式的制造方法
US10150739B2 (en) * 2015-09-10 2018-12-11 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of androgen receptor inhibitor and preparation method thereof
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018009694A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
KR20220028178A (ko) 2016-12-16 2022-03-08 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
ES3018265T3 (en) 2017-04-28 2025-05-14 Astellas Pharma Inc Orally administrable enzalutamide-containing pharmaceutical composition
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN109796437B (zh) * 2019-02-26 2021-08-24 上海健康医学院 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途
WO2020260469A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
JP2023537595A (ja) 2020-08-13 2023-09-04 ファイザー・インク 併用治療
MX2023006911A (es) 2020-12-11 2023-06-26 Ildong Pharmaceutical Co Ltd Nuevos compuestos como inhibidor dual del receptor de androgenos y de la fosfodiesterasa.
MX2023011294A (es) 2021-03-24 2023-10-05 Pfizer Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr.
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
KR102861133B1 (ko) 2021-10-13 2025-09-16 주식회사 엘지에너지솔루션 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN117164520B (zh) * 2022-01-28 2025-04-25 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂及其应用
KR20230170859A (ko) 2022-06-11 2023-12-19 이태영 패스트칫솔
CN117327019A (zh) * 2022-06-23 2024-01-02 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂的应用
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
SU1380610A3 (ru) * 1982-12-06 1988-03-07 Пфайзер Инк. (Фирма) Способ получени спирогетероазолидиндионов или их фармацевтически приемлемых солей
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0748220A4 (en) † 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CA2500977A1 (en) 2002-10-04 2004-04-15 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof in therapeutics
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050005529A1 (en) 2003-07-10 2005-01-13 David Brault Lighting system for a greenhouse
US7718684B2 (en) * 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
AU2005280908A1 (en) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
EP3106162A1 (en) * 2005-05-13 2016-12-21 The Regents of the University of California Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
RS52274B (sr) 2012-10-31
JP2012236843A (ja) 2012-12-06
IL258880A (en) 2018-06-28
IL323480A (en) 2025-11-01
EP1893196B2 (en) 2015-07-29
HK1217103A1 (zh) 2016-12-23
IL187328A (en) 2016-02-29
JP5150780B2 (ja) 2013-02-27
EP1893196A4 (en) 2009-03-18
EP3970721A1 (en) 2022-03-23
JP2012211190A (ja) 2012-11-01
KR20240148945A (ko) 2024-10-11
KR20170107585A (ko) 2017-09-25
RS52274B2 (sr) 2018-05-31
JP2008540523A (ja) 2008-11-20
WO2006124118A1 (en) 2006-11-23
KR20140041831A (ko) 2014-04-04
KR20210136161A (ko) 2021-11-16
JP2021035970A (ja) 2021-03-04
NO342490B1 (no) 2018-06-04
KR20080014039A (ko) 2008-02-13
DK1893196T3 (da) 2012-04-10
DK1893196T4 (en) 2015-10-19
SI1893196T2 (sl) 2015-10-30
NO2017019I1 (no) 2017-05-04
PT2444085E (pt) 2015-06-11
RU2017142159A (ru) 2019-06-05
BRPI0610359B1 (pt) 2020-09-24
KR101579701B1 (ko) 2015-12-22
ZA200710870B (en) 2012-06-27
EP2561871A1 (en) 2013-02-27
ES2378778T5 (es) 2015-09-25
ATE541571T1 (de) 2012-02-15
CY1112798T1 (el) 2015-11-04
KR101332924B1 (ko) 2013-11-26
KR101515335B1 (ko) 2015-04-24
LU92338I2 (fr) 2015-10-27
BRPI0610359B8 (pt) 2021-05-25
JP4644737B2 (ja) 2011-03-02
JP2016183200A (ja) 2016-10-20
CN105037273B (zh) 2019-04-19
JP5138753B2 (ja) 2013-02-06
CN101222922B (zh) 2012-04-18
EP1893196B1 (en) 2012-01-18
PL1893196T5 (pl) 2015-12-31
HK1112856A1 (en) 2008-09-19
SI2444085T1 (sl) 2015-06-30
SI1893196T1 (sl) 2012-06-29
RU2007146462A (ru) 2009-06-20
CN101222922A (zh) 2008-07-16
DK2444085T3 (en) 2015-04-27
ZA201201793B (en) 2015-12-23
EP2444085A1 (en) 2012-04-25
KR101431407B1 (ko) 2014-08-18
JP2015098497A (ja) 2015-05-28
CY2013047I1 (el) 2015-11-04
CN105037273A (zh) 2015-11-11
IL187328A0 (en) 2008-04-13
KR101332889B1 (ko) 2013-11-26
MX394667B (es) 2025-03-21
CN110003114B (zh) 2023-01-17
JP6013535B2 (ja) 2016-10-25
JP2018100292A (ja) 2018-06-28
JP2023075313A (ja) 2023-05-30
CA2608436C (en) 2015-03-24
JP2024153705A (ja) 2024-10-29
KR20120102140A (ko) 2012-09-17
JP2025166151A (ja) 2025-11-05
KR101782236B1 (ko) 2017-09-26
KR20150086567A (ko) 2015-07-28
RU2638833C2 (ru) 2017-12-18
SG10201703816SA (en) 2017-06-29
MX346924B (es) 2017-04-05
RU2448096C3 (ru) 2017-12-11
CA2608436A1 (en) 2006-11-23
KR20110041580A (ko) 2011-04-21
EP1893196A1 (en) 2008-03-05
BRPI0610359A2 (pt) 2010-06-15
IL243812A0 (en) 2016-04-21
HRP20120323T4 (hr) 2015-10-09
ES2378778T3 (es) 2012-04-17
NZ710355A (en) 2017-01-27
ES2535179T3 (es) 2015-05-06
NO20076401L (no) 2008-02-08
KR102481886B1 (ko) 2022-12-28
AU2006248109B2 (en) 2012-11-15
HRP20150437T1 (xx) 2015-06-05
HK1169321A1 (en) 2013-01-25
JP2011068653A (ja) 2011-04-07
MX2022009759A (es) 2022-09-05
KR102713358B1 (ko) 2024-10-02
KR20190104244A (ko) 2019-09-06
KR20230003445A (ko) 2023-01-05
JP2022101657A (ja) 2022-07-06
PL2444085T3 (pl) 2015-07-31
CN110003114A (zh) 2019-07-12
EP3106162A1 (en) 2016-12-21
HRP20120323T1 (en) 2012-05-31
NZ591119A (en) 2012-08-31
KR20140141676A (ko) 2014-12-10
NO2017019I2 (no) 2017-05-04
PL1893196T3 (pl) 2012-06-29
ME01992B (me) 2012-10-30
NZ564223A (en) 2011-03-31
BE2013C074I2 (enExample) 2025-09-17
RS53967B1 (sr) 2015-08-31
AU2006248109A1 (en) 2006-11-23
NO20180225A1 (no) 2008-02-08
KR102020721B1 (ko) 2019-09-10
CN120682155A (zh) 2025-09-23
KR102324567B1 (ko) 2021-11-09
CN116003328A (zh) 2023-04-25
CN102584712A (zh) 2012-07-18
NO20161996A1 (no) 2008-02-08
MX2019015200A (es) 2020-02-05
CY2013047I2 (el) 2015-11-04
MX2007014132A (es) 2008-04-09
JP2019218352A (ja) 2019-12-26
RU2448096C2 (ru) 2012-04-20
EP2444085B1 (en) 2015-03-18
KR20130060369A (ko) 2013-06-07
HUS1300076I1 (hu) 2013-12-17
NO339997B1 (no) 2017-02-27
KR101169832B1 (ko) 2012-07-30

Similar Documents

Publication Publication Date Title
IL258880A (en) Diarylhydantoin compounds
SG170809A1 (en) Diarylthiohydantoin compounds
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
GB2430935A (en) Tetrapeptide analogs
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
EP2099458A4 (en) COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR PRESENTATION AND THERAPY
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer